CN102614355B - Drug composition for treating bedsores - Google Patents
Drug composition for treating bedsores Download PDFInfo
- Publication number
- CN102614355B CN102614355B CN2012100841012A CN201210084101A CN102614355B CN 102614355 B CN102614355 B CN 102614355B CN 2012100841012 A CN2012100841012 A CN 2012100841012A CN 201210084101 A CN201210084101 A CN 201210084101A CN 102614355 B CN102614355 B CN 102614355B
- Authority
- CN
- China
- Prior art keywords
- parts
- drug composition
- radix seu
- seu folium
- cortex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug composition for treating bedsores and a preparation method of the drug composition, and solves the problem of treatment of bedsores. The drug composition is characterized by comprising the following raw materials as per parts by weight: 10 to 30 parts of cacumen biotae, 6 to 12 parts of joe-pye weed, 6 to 12 parts of moutan bark, 15 to 30 parts of alchornea trewioides, 6 to 15 parts of cat's-foot, 5 to 9 parts of common jujube bark, 6 to 12 parts of collett iris root, 6 to 12 parts of cicada ecdysis and 10 to 25 parts of nacre. Clinical trials prove that the drug composition for treating bedsores has the characteristics of good curative effect and high safety, and is worth of being applied clinically and popularized.
Description
[technical field]
The present invention relates to the field of Chinese medicines, be specifically related to treat the pharmaceutical composition of decubital ulcer.
[background technology]
Decubital ulcer claims pressure ulcer again, and pressure ulcer is because the long-term pressurized of local organization, continuous ischemia, anoxia, malnutrition take place and causes tissue fester's necrosis, is stubborn problem comparatively in the nursery work.According to relevant bibliographical information, general hospital incidence rate is 2.5%～8.8%, even up to 11.6%, has every year 60000 people to die from the decubital ulcer complication approximately.Modern medicine thinks that the reason that decubital ulcer produces is that local organization suffers persistence pressure at right angle etc. more, and the local blood circulation obstacle causes the ulcer necrosis.The body endogenous cause of ill is also participated simultaneously, and the prolonged illness bed causes basal metabolism poor, the energy Deficiency of Intake, and Abwehrkraft des Koepers descends, and pathogen susceptibilitys such as escherichia coli, staphylococcus aureus increase.The antibiotics coating is roughly adopted in treatment, but this class medicine has stronger zest to wound surface, and easy damaged new granulation tissue when changing dressings is unfavorable for the healing and the regeneration of wound surface.
[summary of the invention]
Technical assignment of the present invention is at above the deficiencies in the prior art, provides a kind of curative effect certainly and the pharmaceutical composition of the little treatment decubital ulcer of side effect.
The technical scheme that the present invention solves its technical problem is: a kind of pharmaceutical composition for the treatment of decubital ulcer is characterized in that being made by following materials of weight proportions medicine: 10～30 parts of Cacumen Platycladis, 6～12 parts of Herba Lycopi, 6～12 parts of Cortex Moutans, 15～30 parts of Radix seu Folium Alchorneae trewioidis, 6～15 parts of Radix seu Folium Gaultheriae Forrestiis, 5～9 parts of Cortex Jujubae, 6～12 parts of little palm fibre bags, 6～12 parts of Periostracum Cicadaes, 10～25 parts of Concha Margaritiferas.
Optimizing weight proportion is: 20 parts of Cacumen Platycladis, 10 parts of Herba Lycopi, 10 parts of Cortex Moutans, 20 parts of Radix seu Folium Alchorneae trewioidis, 12 parts of Radix seu Folium Gaultheriae Forrestiis, 6 parts of Cortex Jujubae, 10 parts of little palm fibre bags, 10 parts of Periostracum Cicadaes, 20 parts of Concha Margaritiferas.
Wherein said:
Cacumen Platycladi is twig and the leaf of Cupressaceae plant Cacumen Platycladi.Bitter, puckery, cold.Return lung, liver, spleen channel.Removing heat from blood, hemostasis, wind-damp dispelling, toxic swelling looses.
The Herba Lycopi is the stem and leaf of labiate lycopus lucidus.Toil, tepor.Go into liver, spleen channel.Invigorate blood circulation row water.
Cortex Moutan is the dry root bark of ranunculaceae peony, but the merit clearing away heat and cooling blood, promoting blood circulation to remove blood stasis.
Radix seu Folium Alchorneae trewioidis is root, the leaf of the red back of the body Cortex Alchorneae Davidii of euphorbia plant.Sweet; Cool.Return bladder; Large intestine; Lung meridian.Clearing away heat-damp and promoting diuresis; Removing pathogenic heat from blood and toxic substance from the body; Killing parasites for relieving itching.
Radix seu Folium Gaultheriae Forrestii is the white saturating sliding herb that disappears of Labiatae bar thing.Acrid in the mouth; Warm in nature.Expelling wind and activating blood circulation; Eliminating damp, detoxifying.
Cortex Jujubae is the bark of Rhamnaceae plant Fructus Jujubae.Toil, tepor.Return large intestine; Lung meridian.Convergence, antiinflammatory, pain relieving, antipruritic.
Little palm fibre bag is root and the herb of Liliaceae Li Lu platymiscium Mengzi Li Lu.Promoting blood circulation to remove blood stasis, hemostatic analgesia, emetic diuretic.
Periostracum Cicadae, exuviae shell when sprouting wings, the merit wind heat extraction that can loose, sore-throat relieving, rash, nebula removing, spasmolytic for the larva of cicada Cryptotympana atrata Fabr..
Concha Margaritifera is the shellfish nacreous layer, but the merit suppressing the hyperactive liver and subsiding YANG, the arresting convulsion of calming the nerves, liver heat removing and eyesight improving, convergence.
Composition principle: old laid up bed, yang-energy is not transported, cloudy flow of QI being obstructed, QI and blood is blocked, failure of skin and muscle to be nourished, if merge evil poison or damp invasion, strongly fragrant heat-transformation of a specified duration, heat is stopped up the meat corruption, can increase the weight of the skin diabrosis, makes the course of disease touching, and open sore part difficulty is held back.The present invention adopts promoting blood circulation and detoxication, and the dampness removing pain relieving is the rule of treatment.In the side: the Cacumen Platycladi cooling blood for hemostasis, wind-damp dispelling, toxic swelling looses; Herba Lycopi, Cortex Moutan, little palm fibre bag have the effect of removing heat from blood and promoting blood circulation; Radix seu Folium Alchorneae trewioidis, Radix seu Folium Gaultheriae Forrestii clearing away heat-damp and promoting diuresis; Removing pathogenic heat from blood and toxic substance from the body; Cortex Jujubae convergence, antiinflammatory, pain relieving; Periostracum Cicadae is drawn all medicines and walks skin and walk table, and the effect of diffusing wind heat extraction is arranged; Concha Margaritifera has the merit of astringent therapy.Modern pharmacological research shows that Cortex Jujubae has bacteriostasis to staphylococcus aureus, escherichia coli pathogenic microorganism; Radix seu Folium Alchorneae trewioidis has inhibitory action to escherichia coli, Bacillus typhi, dysentery bacterium, bacillus pyocyaneus, Bacillus proteus; Little palm fibre bag has anti-inflammation, reduces whole blood and plasma viscosity, reduces packed cell volume, and anticoagulant prevents pharmacological actions such as thrombosis; Cacumen Platycladi has broad-spectrum antibacterial action, but the vasodilation that facedown inflammation intralesional H+ concentration raises and to cause, and can leukocyte increasing engulf the ability of pathogen, and suppress the formation of antibacterial coagulase, help engulfing of reticuloendothelial system.
[specific embodiment]
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, the crude drug weight proportion: 10 parts of Cacumen Platycladis,, 6 parts of Herba Lycopi, 6 parts of Cortex Moutans, 15 parts of Radix seu Folium Alchorneae trewioidis, 6 parts of Radix seu Folium Gaultheriae Forrestiis, 5 parts of Cortex Jujubae, 6 parts of little palm fibre bags, 6 parts of Periostracum Cicadaes, 10 parts of Concha Margaritiferas.
Embodiment 2, the crude drug weight proportion: 20 parts of Cacumen Platycladis, 10 parts of Herba Lycopi, 10 parts of Cortex Moutans, 20 parts of Radix seu Folium Alchorneae trewioidis, 12 parts of Radix seu Folium Gaultheriae Forrestiis, 6 parts of Cortex Jujubae, 10 parts of little palm fibre bags, 10 parts of Periostracum Cicadaes, 20 parts of Concha Margaritiferas.
Embodiment 3, the crude drug weight proportion: 30 parts of Cacumen Platycladis, 12 parts of Herba Lycopi, 12 parts of Cortex Moutans, 30 parts of Radix seu Folium Alchorneae trewioidis, 15 parts of Radix seu Folium Gaultheriae Forrestiis, 9 parts of Cortex Jujubae, 12 parts of little palm fibre bags, 12 parts of Periostracum Cicadaes, 25 parts of Concha Margaritiferas.
Chinese medicine of the present invention can be prepared from by following method: all medicine mixings are added 3 times of water yields, decoct 2 times, each 1 hour, collecting decoction left standstill.Adopt the bedsore wound soak during use.Every day 2 times, each 2 hours.
Effective combination of said medicine is coordinated mutually, effectively reach the purpose of treatment decubital ulcer, and side effect is less.The above results is that clinical data proves that fully interrelated data is as follows, wherein studies drug use and is the crude drug weight proportion among the embodiment 2.
1 object and method
1.1 object: select outpatient service and inpatient totally 80 examples, be the local skin pressurized and cause, all meet in " clinical disease diagnosis and curative effect judging standard " diagnosis about decubital ulcer.Be divided into two groups at random: 40 examples are organized in treatment, male 21 examples, women 19 examples; 58～92 years old age, 68.2 years old mean age; The middle decubital ulcer of foundation " basic nursing rule of operation " is standard by stages: I phases 8 example, II phases 8 example, III phases 15 example, IV phases 9 example.Matched group 40 examples, male 22 examples, women 18 examples; Age 59-94 year, 68.5 years old mean age; Decubital ulcer is I phases 9 example by stages, II phases 12 example, III phases 11 example, IV phases 8 example.Two groups of sexes, age, the state of an illness, body constitution, nutriture, decubital ulcer position, areas compare, and difference does not have significance meaning (P＞0.05), has comparability.
1.2 method
1.2.1 treatment group: the skin before the treatment around the routine disinfection decubital ulcer, dried with wiping away behind the normal saline cleaning wound surface, the medicine that the embodiment of the invention 2 is obtained carries out the bedsore wound soak.Every day 2 times, each 2 hours.
1.2.2 matched group:, local behind the skin before the treatment around the routine disinfection decubital ulcer with the bedsore wound soak of tobramycin 80,000 units with iodine tincture coating wound surface.Every day 2 times, each 2 hours.
1.2.3 criterion of therapeutical effect: draft with reference to " clinical disease diagnosis and curative effect judging standard ".Recovery from illness: the ulcer incrustation also comes off, and local organization is repaired fully; Produce effects: the ulcer incrustation, the ulcer area dwindles; Effectively: the ulcer area dwindles, shoals, and exudate reduces; Invalid: local no change or increase the weight of.
1.2.3 statistical analysis SPSS 13.0 carries out statistical analysis.
2 results
2.1 two groups of clinical efficacies relatively: add up behind the medication 7d, clinical efficacy sees the following form.Total effective rate treatment group is 95.0%, and matched group is 72.5%, and treatment group total effective rate is apparently higher than matched group (P＜0.05).
Table two group clinical efficacy is (example) relatively
2.2 adverse reaction rate: all do not find obvious adverse reaction for two groups.
3. conclusion: the prompting of this result of study, the present invention treats decubital ulcer and has good effect and the higher characteristics of safety, is worth clinical practice, popularization.
Claims (2)
1. a pharmaceutical composition for the treatment of decubital ulcer is characterized in that being processed into by following materials of weight proportions medicine: 10 ~ 30 parts of Cacumen Platycladis, 6 ~ 12 parts of Herba Lycopi, 6 ~ 12 parts of Cortex Moutans, 15 ~ 30 parts of Radix seu Folium Alchorneae trewioidis, 6 ~ 15 parts of Radix seu Folium Gaultheriae Forrestiis, 5 ~ 9 parts of Cortex Jujubae, 6 ~ 12 parts of little palm fibre bags, 6 ~ 12 parts of Periostracum Cicadaes, 10 ~ 25 parts of Concha Margaritiferas.
2. a kind of pharmaceutical composition for the treatment of decubital ulcer according to claim 1 is characterized in that being processed into by following materials of weight proportions medicine: 20 parts of Cacumen Platycladis, 10 parts of Herba Lycopi, 10 parts of Cortex Moutans, 20 parts of Radix seu Folium Alchorneae trewioidis, 12 parts of Radix seu Folium Gaultheriae Forrestiis, 6 parts of Cortex Jujubae, 10 parts of little palm fibre bags, 10 parts of Periostracum Cicadaes, 20 parts of Concha Margaritiferas.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100841012A CN102614355B (en) | 2012-03-27 | 2012-03-27 | Drug composition for treating bedsores |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100841012A CN102614355B (en) | 2012-03-27 | 2012-03-27 | Drug composition for treating bedsores |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102614355A CN102614355A (en) | 2012-08-01 |
| CN102614355B true CN102614355B (en) | 2013-07-24 |
Family
ID=46554803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100841012A Active CN102614355B (en) | 2012-03-27 | 2012-03-27 | Drug composition for treating bedsores |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102614355B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103356753B (en) * | 2013-06-24 | 2014-09-24 | 李娜 | Traditional Chinese medicine for treating pressure sores |
| CN104474213A (en) * | 2014-12-19 | 2015-04-01 | 孙晓兵 | Traditional Chinese medicine paste for treating bed sores and preparation method of traditional Chinese medicine paste |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541666A (en) * | 2003-04-29 | 2004-11-03 | 深圳市东方本草科技开发有限公司 | Chinese traditional medicine composition for treating bedsore and acute soft tissue injury |
| CN101313959A (en) * | 2008-06-06 | 2008-12-03 | 叶志军 | Plaster medicament for treating scabies |
| CN101569696A (en) * | 2009-06-01 | 2009-11-04 | 孙爱莲 | Chinese medicament for traumatic wound |
-
2012
- 2012-03-27 CN CN2012100841012A patent/CN102614355B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541666A (en) * | 2003-04-29 | 2004-11-03 | 深圳市东方本草科技开发有限公司 | Chinese traditional medicine composition for treating bedsore and acute soft tissue injury |
| CN101313959A (en) * | 2008-06-06 | 2008-12-03 | 叶志军 | Plaster medicament for treating scabies |
| CN101569696A (en) * | 2009-06-01 | 2009-11-04 | 孙爱莲 | Chinese medicament for traumatic wound |
Non-Patent Citations (4)
| Title |
|---|
| 张琴等.披麻草根的研究进展.《中国药业》.2005,第14卷(第7期),第85-86页. |
| 披麻草根的研究进展;张琴等;《中国药业》;20050731;第14卷(第7期);第85-86页 * |
| 褥疮的中医药治疗现状;高月平等;《中华中医药杂志》;20081031;第23卷(第10期);第908-909页 * |
| 高月平等.褥疮的中医药治疗现状.《中华中医药杂志》.2008,第23卷(第10期),第908-909页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102614355A (en) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100574778C (en) | The compound Chinese medicinal preparation of treatment acne | |
| CN102836367B (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| CN101406557A (en) | External-use Chinese medicine for treating burn, scald and various skin injuries | |
| CN108186711A (en) | Promote the pharmaceutical composition of wound healing | |
| CN112245497A (en) | Chinese medicinal preparation for sterilizing, diminishing inflammation and promoting wound healing and preparation method thereof | |
| CN111297961A (en) | Dong medicine for promoting wound healing | |
| CN102309596A (en) | Traditional Chinese medicine powder for controlling fish enteritis and preparation method thereof | |
| CN102614355B (en) | Drug composition for treating bedsores | |
| CN104491213A (en) | Traditional Chinese ointment for treating bedsores | |
| CN105126235A (en) | Skin wound treating system used for debridement and drug administration and oxygen supply | |
| CN102357164A (en) | Medicine composition for clinical care of burns and preparation method thereof | |
| CN204723468U (en) | A kind of skin wound treatment system for wound debridement, administration oxygen supply | |
| CN111166859A (en) | Foot bath powder and preparation method thereof | |
| CN102018703B (en) | Azulene sulfonate-containing gynaecological special lotion | |
| CN106377602A (en) | Dendrobium officinale composite disinfection powder, and preparation method and application method thereof | |
| CN103463516A (en) | Traditional Chinese medicine ointment for treating dermatophytoses and preparation method thereof | |
| CN103251691B (en) | Chinese medicine formula for treating bovine mastitis as well as extract and preparation thereof | |
| CN101391065A (en) | Compound momordica seed pepper soup for treating urgent chronic pelvic inflammatory disease | |
| CN101332286B (en) | Traditional Chinese medicine composition for treating skin disease and preparation method thereof | |
| CN102824440B (en) | Traditional Chinese medicine composition for treating dairy cow mastitis and preparation method thereof | |
| CN1246001C (en) | 'Fufukang' Chinese traditional medicine preparation and preparing process thereof | |
| CN105168503B (en) | It is a kind of to be used to prevent external medicine composition of radiodermatitis and preparation method thereof | |
| CN101214280B (en) | Chinese medicine for treating burn, scald and sores and preparation thereof | |
| CN101036712A (en) | Scald and burn ointment | |
| CN103933417A (en) | Traditional Chinese medicine preparation for treating skin diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 541299 No. 162, Lingchuan Avenue, Lingchuan County, Guilin, the Guangxi Zhuang Autonomous Region Patentee after: Sun Jing Address before: 276826 Rizhao People's Hospital, 126 Tai'an Road, Shandong, Rizhao City, China Patentee before: Sun Jing |
|
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SUN JING Effective date: 20140912 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 541299 GUILIN, GUANGXI ZHUANG AUTONOMOUS REGION TO: 226200 NANTONG, JIANGSUPROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140912 Address after: 226200 chemical industry park, Nantong, Jiangsu, Qidong Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Address before: 541299 No. 162, Lingchuan Avenue, Lingchuan County, Guilin, the Guangxi Zhuang Autonomous Region Patentee before: Sun Jing |